These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2573862)

  • 1. New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation.
    Duvoisin RC
    Neurology; 1989 Nov; 39(11 Suppl 2):4-6. PubMed ID: 2573862
    [No Abstract]   [Full Text] [Related]  

  • 2. New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings.
    Neurology; 1989 Nov; 39(11 Suppl 2):1-106. PubMed ID: 2586761
    [No Abstract]   [Full Text] [Related]  

  • 3. Factors influencing dopaminergic therapy of Parkinson's disease.
    Horowski R
    Funct Neurol; 1988; 3(4):459-70. PubMed ID: 2907501
    [No Abstract]   [Full Text] [Related]  

  • 4. New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists.
    Goetz CG
    Exp Neurol; 1997 Mar; 144(1):17-20. PubMed ID: 9126145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current approaches in the treatment of Parkinson disease].
    Caraceni T; Geminiani G; Tamma F
    Recenti Prog Med; 1989 Dec; 80(12):686-91. PubMed ID: 2576471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.
    Riederer P; Gerlach M; Müller T; Reichmann H
    Parkinsonism Relat Disord; 2007 Dec; 13(8):466-79. PubMed ID: 17919963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis and therapy of Parkinson's disease].
    Wittstock M; Benecke R
    MMW Fortschr Med; 2005 May; 147 Spec No 2():28-31. PubMed ID: 15968869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease.
    Avanzi M; Uber E; Bonfà F
    Neurol Sci; 2004 Jun; 25(2):98-101. PubMed ID: 15221629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on the management of Parkinson's disease.
    Standaert DG; Stern MB
    Med Clin North Am; 1993 Jan; 77(1):169-83. PubMed ID: 8093493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled-release dopamine polymers as a novel approach to the treatment of Parkinson's disease.
    Sabel BA; Freese A; During MJ
    Adv Neurol; 1990; 53():513-8. PubMed ID: 2239492
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypersexuality due to dopaminergic drugs.
    Prescrire Int; 2005 Dec; 14(80):224. PubMed ID: 16400746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine agonists for Parkinson's disease.
    Drug Ther Bull; 1991 Jan; 29(2):7-8. PubMed ID: 1682118
    [No Abstract]   [Full Text] [Related]  

  • 13. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies.
    Hodaie M; Neimat JS; Lozano AM
    Neurosurgery; 2007 Jan; 60(1):17-28; discussion 28-30. PubMed ID: 17228250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current aspects in the therapy of Parkinson's Syndrome].
    Ceballos-Baumann A
    Krankenpfl J; 1991; 29(7-8):310-4. PubMed ID: 1681135
    [No Abstract]   [Full Text] [Related]  

  • 16. Description (reporting the actual words used in written letters) of the neuropsychological and psychopathological modifications produced by dopaminergic treatment in a young patient with Parkinson's disease.
    Cannas A; Solla P; Floris G; Tacconi P; Fulgheri P; Congia S; Spissu A
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):138-40. PubMed ID: 16033704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease: the case for novel treatment strategies.
    Stern MB; Freese A
    Exp Neurol; 1997 Mar; 144(1):2-3. PubMed ID: 9126142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Continuous dopaminergic stimulation in Parkinson disease].
    Obeso JA; Luquin MR; Vaamonde J; Grandas F; Pastor MA; Artieda J; Martínez-Lage JM
    Neurologia; 1987; 2(5):227-34. PubMed ID: 2908545
    [No Abstract]   [Full Text] [Related]  

  • 19. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 20. [Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].
    Destée A; Bordet R
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S69-82. PubMed ID: 12690666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.